Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 54135419RSD4001 | Other Identifier | Jannsen Cilag S.A. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries: Argentina, Brazil, Colombia and Mexico; and to evaluate all and depression-related healthcare resource utilization in TRD participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with Diagnosis of Depression | Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Treatment Resistant Depression (TRD) | Prevalence of TRD will be assessed as percentage of participants with TRD among Major Depressive Disorder (MDD) participants. | Baseline (Day 1) |
| Healthcare Resource Utilization in TRD Participants | Healthcare resources utilized in TRD participants will be estimated. | Up to Month 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic Characteristics of TRD Participants | Demographic characteristics (such as age and gender) of TRD participants will be assessed at baseline. | Baseline (Day 1) |
| Number of Participants With Comorbid Conditions |
Not provided
Inclusion Criteria:
Phase 1:
Phase 2:
Diagnosis of Treatment Resistant Depression (TRD), to be described by the investigator, based on the criteria:
Adequate follow-up and treatment with at least 2 antidepressants
Without complete response to treatment (based on Montgomery-Asberg Depression Rating Scale [MADRS])
Exclusion Criteria:
Participants diagnosed of psychosis, schizophrenia, bipolar disorder, schizoaffective disorder, or dementia
Participants with substance dependence considered serious by the investigator
Participant currently participating in another clinical study
Not provided
Not provided
Not provided
Study population consists of participants with Major Depressive Disorder (MDD) being treated in a psychiatry reference site (clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries and will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) among MDD participants.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jannsen Cilag S.A. Clinical Trial | Jannsen Cilag S.A. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales | Buenos Aires | C1425AHQ | Argentina | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34463905 | Derived | Soares B, Kanevsky G, Teng CT, Perez-Esparza R, Bonetto GG, Lacerda ALT, Uribe ES, Cordoba R, Lupo C, Samora AM, Cabrera P. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study. Psychiatr Q. 2021 Dec;92(4):1797-1815. doi: 10.1007/s11126-021-09930-x. Epub 2021 Aug 31. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Comorbid conditions of TRD participants will be assessed at baseline.
| Baseline (Day 1) |
| Treatment Patterns Over Time for TRD Participants | Treatment patterns of TRD participants will be assessed over time. | Baseline (Day 1) up to Month 12 |
| Treatment Duration for MDD | Treatment duration is defined as the time interval between baseline and time to next therapy (since the date of the first and second regimen to the start of third regimen). | Baseline (Day 1) up to Month 12 |
| Treatment Pattern for TRD Participants by Line | Treatment patterns for TRD participants will be determined by distribution of every line of the treatment regimen including pharmaceutical and non-pharmaceutical treatments. | Baseline (Day 1) up to Month 12 |
| Sequence of Drugs | Sequence of drugs taken by TRD participants will be determined. | Baseline (Day 1) up to Month 12 |
| Severity of Symptoms as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Score | The MADRS is a 10 item scale for the evaluation of depressive symptoms (Montgomery et al 1979). The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. Each MADRS item is rated on a 0 to 6 scale with a total score ranging from 0 60. Higher MADRS scores indicate higher levels of depressive symptoms (more severe condition) and lower scores indicate a decreased severity of depression. | Baseline (Day 1), Month 3, 6, 9 and 12 |
| Level of Disability as Measured by Sheehan Disability Scale (SDS) | SDS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. To get a total score add up the 3 individual scores and the total score ranges from "0 = unimpaired" to "30 = highly impaired". Higher scores indicate worsening. | Baseline (Day 1), Month 6, and 12 |
| Suicidality Risk (Ideation and Attempts) as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Score | Suicidal ideation or behavior will be measured using C SSRS score. C-SSRS is a clinician rated assessment of suicidal behavior and/ or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 yes/no items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. | Baseline (Day 1), Month 3, 6, 9, and 12 |
| Healthcare Costs in TRD Participants | Total healthcare costs and healthcare costs related to depression will be determined in TRD participants. | Up to Month 12 |
| Indirect Cost Associated With Work Productivity Loss | Work productivity loss was measured by Work Productivity and Activity Impairment Questionnaire (WPAI). The WPAI is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on the job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. | Baseline (Day 1) up to Month 12 |
| Indirect Cost Associated With Daily Functioning Loss | Indirect cost associated with daily functioning loss will be determined. | Baseline (Day 1) up to Month 12 |
| Indirect Cost Associated With Caregiver Burden | Indirect cost associated with caregiver burden will be determined. | Baseline (Day 1) and Month 12 |
| Indirect Cost Associated With Quality of Life | Quality of life will be measured by EuroQol-5 Dimension (EQ-5D). The EQ-5D descriptive system comprises the following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 3 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." The descriptive system can be represented as a health state. The EQ-VAS self-rating records the respondent's own assessment of his or her overall health status, on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). | Baseline (Day 1) and Month 12 |
| Instituto DAMIC |
| Córdoba |
| X5003DCE |
| Argentina |
| Clinica Privada de Salud Mental Santa Teresa de Ávila | La Plata | B1904ADM | Argentina |
| CESASIN | Mendoza | 5500 | Argentina |
| C I A P Centro de investigacion y Asistencia en Psiquiatria | Rosario | 2000 | Argentina |
| Universidade Federal De Minas Gerais - Hospital das Clínicas | Belo Horizonte | 30130-100 | Brazil |
| Instituto De Neurociencias Dr. Quevedo Hospital Sao Sebastiao | Criciúma | 88801-250 | Brazil |
| Trial Tech Tecnologia em Pesquisas com Medicamentos | Curitiba | 80240-280 | Brazil |
| Universidade Federal Do Ceara | Fortaleza | 60020-181 | Brazil |
| Instituto Bairral de Psiquiatria | Itapira | 13970-905 | Brazil |
| Faculdade de Medicina da Universidade Federal de Pelotas | Pelotas | 96030-002 | Brazil |
| Hospital das Clinicas de Porto Alegre | Porto Alegre | 90035-903 | Brazil |
| Universidade Federal do Rio de Janeiro - Instituto de Psiquiatria | Rio de Janeiro | 22290-140 | Brazil |
| Hospital Universitario Professor Edgar Santos | Salvador | 40110-060 | Brazil |
| Hospital Das Clinicas Da Faculdade De Medicina Da USP | São Paulo | 05403-903 | Brazil |
| HOMO - ESE Hospital Mental de Antioquia | Bello | 051053 | Colombia |
| Instituto Colombiano del Sistema Nervioso | Bogotá | 110121 | Colombia |
| Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda. | Bogotá | 111166 | Colombia |
| Conciencia S.A.S | Medellín - Antioquia | 050021 | Colombia |
| Hospital Psiquiátrico Granja la Salud Tlazolteotl | Ixtapaluca | 56530 | Mexico |
| Hospital Aranda de la Parra S A de C V | León | 37000 | Mexico |
| Grupo de Estudios Médicos y familiares Carraci SC | Mexico City | 03740 | Mexico |
| Estimulación Magnética Transcraneal de México S.C. | Mexico City | 11006 | Mexico |
| Hospital Psiquiatrico Fray Bernardino Alvarez | Mexico City | 14000 | Mexico |
| Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz | Mexico City | 14370 | Mexico |
| Clínica de Neuropsiquiatría Tlatelolco ISSSTE | Mexico City | 6900 | Mexico |
| Instituto Nacional de Neurología y Neurocirugía | México | 14269 | Mexico |
| Privarte Practice of Dr. Javier Zambrano | México | 15900 | Mexico |
| Instituto Jalisciense de Salud Mental | México | 45170 | Mexico |
| Centro para las Adicciones y Salud Mental S.A. de C.V. | Monterrey | 64060 | Mexico |
| cit NEUROPSIQUE | Monterrey | 64610 | Mexico |
| Hospital Central Dr Ignacio Morones Prieto | San Luis Potosí City | 78240 | Mexico |
| Clínica de Consulta Externa Alfredo del Mazo Vélez ISSEMyM | Toluca | 50080 | Mexico |
| ID | Term |
|---|---|
| D061218 | Depressive Disorder, Treatment-Resistant |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided